The B-MoGen team has some of the best and brightest minds in genome engineering. They are tenacious, deeply curious and committed to helping create new, effective patient therapies.
Jeff S. Liter, MBA
President and CEO
Jeff is a senior executive with a proven track record at profitably growing emerging companies and business divisions. His experience developing businesses to 1st and 2nd market positions, raising over $3.2 million for prior start-ups, and leading start-to-finish M&A transactions from $4 million to over $2 billion. Jeff comes to B-MoGen after serving for two years as COO of a cGMP cellular therapy company where in his first year he completed a turnaround of their CDMO services to its’ first ever profitable status. As the business leader in B-MoGen Biotechnologies, Jeff aims to enable the company to become an industry leader in gene editing.
Branden S. Moriarity, Ph.D.
Chief Scientific Officer
Dr. Moriarity is an expert in genome engineering using both cut and paste DNA transposon systems, such as Sleeping Beauty and piggyBac, and both TALEN and CRISPR targeted nuclease platforms. These technologies are at the core of B-MoGen Biotechnologies, Inc. He spent five years as a graduate student and 2 years as a postdoctoral fellow at the University of Minnesota working with Dr. David A. Largaespada, an authority on mouse genetics, gene modification, cancer genes, and disease models. He was ‘fast tracked’ to the position of Assistant Professor in the Department of Pediatrics at the University of Minnesota in 2014.
David A. Largaespada, Ph.D.
Chairman, Scientific Advisory Board
Dr. Largaespada is an authority on mouse genetics, gene modification, cancer genes, and disease models. His outstanding background was integral to the founding of B-MoGen Biotechnologies, Inc. He spent five years as a postdoctoral fellow in Frederick, Maryland at the National Cancer Institute working with world-renowned geneticists Dr. Nancy Jenkins and Dr. Neal Copeland, where the Leukemia and Lymphoma Society of America awarded him a postdoctoral fellowship. He is currently a Full Professor in the Department of Pediatrics and the Department of Genetics, Cell Biology and Development at the University of Minnesota.
Beau R. Webber, Ph.D.
Chief Technology Officer
Dr. Webber is an expert in the areas of stem cell biology, hematology and immunology, and genetic engineering. He has extensive experience in the genetic modification of both human and mouse cell lines, primary cell types including lymphocytes and hematopoietic stem cells, and pluripotent cells including embryonic stem cells (ESC) and induced pluripotent stem cells (iPSC) using targeted nucleases such as TALEN and CRISPR/Cas9, as well as cut and paste transposon systems such as Sleeping Beauty and piggyBAC. Dr. Webber graduated summa cum laude from the University of Wisconsin with a B.S. in Cellular and Molecular Biology and was voted by faculty as Outstanding Senior of the Year in the Cellular and Molecular Biology program. He conducted his PhD studies at the University of Minnesota as a fellow in the Stem Cell Institute training program under the mentorship of Drs. Bruce Blazar and Jakub Tolar. As a postdoctoral fellow in the Hematology, Oncology, and Transplantation program, Dr. Webber developed advanced strategies for genetic modification of primary human lymphohematopoietic and pluripotent stem cells for cancer immunotherapy and correction of inherited diseases. Dr. Webber has published numerous peer-reviewed articles in the areas of stem cell biology, hematology, and genome engineering and is currently an Assistant Professor in the Department of Pediatrics, Division of Hematology and Oncology at the University of Minnesota.
Kristin Taylor Geisler
Chief Financial Officer
Kristin is a senior finance executive known for providing hands-on finance leadership for building and reengineering capabilities in dynamic organizations. An MBA/CPA with an extensive track record of delivering scalable and sustainable solutions in areas from accounting to budgeting, financial analysis and reporting, along with significant experience in liquidity, capital markets, investing and risk management. She has diverse industry experience from start-ups to an industry leading medical device organization, and is skilled in identifying and implementing capabilities to improve efficiency and quality. Previous to her corporate experience, she worked for three years in public accounting.